Schrödinger To Present New Preclinical Data From Its Wee1 Inhibitor Program At AACR Annual Meeting 2022
Schrödinger, Inc. (Nasdaq: SDGR) announced promising preclinical data on its small-molecule Wee1 inhibitors, to be presented at the AACR Annual Meeting in New Orleans (April 8-13, 2022). These inhibitors may induce apoptosis in tumor cells by triggering DNA damage. Early studies show significant anti-tumor activity in ovarian and uterine cancers. Schrödinger plans to select a development candidate later this year, with an emphasis on strong pharmacodynamics and potential use as monotherapy or in combination therapy.
- Promising anti-tumor activity of Wee1 inhibitors in preclinical studies.
- Potential for best-in-class profile, allowing for monotherapy and combination therapy applications.
- Plans to select a development candidate later in the year.
- None.
Wee1 is a gatekeeper checkpoint kinase that prevents cellular progression through the cell cycle, allowing time for DNA repair before cell division takes place. Inhibition of Wee1 allows for accumulation of DNA damage, triggering DNA breakage and apoptosis in tumor cells. Data from third party clinical studies are showing promising anti-tumor activity in solid tumors, including ovarian and uterine cancer. Schrödinger has identified multiple highly selective Wee1 inhibitors with optimized physicochemical properties that show strong pharmacodynamic responses and anti-tumor activity in preclinical models. This potentially best-in-class profile may position these structurally distinct Wee1 inhibitors for applications both as monotherapy and as combination therapy with other agents. Schrödinger expects to select a Wee1 development candidate later this year.
Details of the poster presentation are as follows:
Title: Discovery of potent, selective, and orally available Wee1 inhibitors that demonstrate increased DNA damage and mitosis in tumor cells leading to tumor regression in vivo
Abstract number: 2570
Date & time:
Location:
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has over 650 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com follow us on LinkedIn and Twitter, or visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to, those statements regarding the clinical potential of Wee1 inhibitors, the properties of the Wee1 inhibitors that we have identified, the potential for our Wee1 inhibitors to be used as monotherapy or as a combination therapy with other agents, and our expected timing for selecting a development candidate for our Wee1 program. Statements including words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond our control, including the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and our ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of IND submissions, clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business and other risks detailed under the caption “Risk Factors” and elsewhere in our
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005278/en/
Investors:
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264
Media:
Schrödinger, Inc.
tracy.lessor@schrodinger.com
617-519-9827
Source: Schrödinger, Inc.
FAQ
What new data did Schrödinger announce regarding its Wee1 inhibitors?
When and where will the findings about Wee1 inhibitors be presented?
What types of cancer have shown promising results with Wee1 inhibitors?
What are the expected next steps for Schrödinger's Wee1 inhibitors?
How do Wee1 inhibitors affect tumor cells?
